Antibodies specific for type II mutant EGTR

US5212290A · kind A · utility

Assignees

• THE JOHNS HOPKINS UNIVERSITY · US
• Duke University · US

Inventors

• Bert Vogelstein · Baltimore, US
• Darell Bigner · Mebane, US

Key dates

• Filing date: Dec 17, 1990
• Grant date: May 18, 1993
• Expiry date: Dec 17, 2010

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/812
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Polyclonal and monoclonal antibodies which recognize mutant epidermal growth factor receptors (EGFR) have been produced. The EGFR gene is amplified in 40% of malignant gliomas and frequently the amplified genes are rearranged. Internal deletions in four glioma cell lines created an epitope which was not present in normal EGFR. These mutant were characterized as expressing mutant type 1I EGFR and were found in a small percent of gliomas. Antibodies against these epitopes are useful for diagnosis of specific gliomas which express mutant type 1I EGFR.